Bulimia nervosa (BN) is a serious disorder characterized by recurrent large-volume eating episodes that are marked by a loss of control (binge eating), regular compensatory behaviors that are intended to prevent weight gain (purging), and over-valuation of body shape and weight. BN is associated with psychiatric comorbidity, significant psychosocial impairment, medical complications, and increased mortality.
Clinical guidelines for the evidence-based treatment of BN highlight first-line, outpatient psychotherapeutic and pharmacological approaches. Self-help, enhanced cognitive-behavioral therapy (CBT), and interpersonal psychotherapy are considered first-line psychotherapeutic interventions. Antidepressants, most notably SSRIs and specifically fluoxetine, which is FDA-approved for use in BN, are recommended adjunctive first-line treatments. Limited data suggest that CBT-BN alone and CBT-BN plus antidepressants are more efficacious than antidepressants alone.1 Despite these available treatment options, roughly 30% of cases are chronic and unremitting. Even for those who do initially respond to treatment, estimated rates of relapse in BN range from 25% to 63%.2
Melia is a patient with treatment-refractory, complex BN, who presents for treatment at our eating disorders program. A 20-year-old college student, she plans to attend law school after graduation.
Her eating disorder began in her freshman year, when she started “using food to cope” after a difficult breakup and domestic violence. Before admission, she was eating salads or diet frozen entrées for most meals and binge eating and purging 3 to 5 times a day. She has a history of self-harming behaviors and 2 suicide attempts.
She reports frequent shoplifting, occasional binge drinking to the point of blacking out, and recurrent unsafe sex with men she meets at bars. She previously had attempted outpatient, partial hospital, and residential treatment but had been unable to sustain recovery. She also had several trials of antidepressant medication without response for depression, anxiety, and eating-disordered symptoms.
Melia reports that she feels “very stressed” at school and has high standards for herself. She has had to withdraw from school several times to pursue treatment.
Improving outcomes for individuals with treatment-resistant BN such as Melia hinges on:
1 Developing an understanding of what factors make treatment failure or dropout more likely
2 Generating hypotheses about the mechanisms of non-response
3 Proposing and evaluating treatments that address these hypothesized mechanisms
Dr. Anderson is Clinical Associate Professor, Dr. Reilly is Postdoctoral Fellow, Dr. Berner is Postdoctoral Fellow, Dr. Trunko is Clinical Associate Professor, and Dr. Kaye is Professor and Director, Eating Disorders Center, Department of Psychiatry, University of California, San Diego, CA.
The authors report no conflicts of interest concerning the subject matter of this article.
1. Wilson G, Shafran R. Eating disorders guidelines from NICE. Lancet. 2005;365:79081.
2. Keel P, Dorer D, Franko D, et al. Postremission predictors of relapse in women with eating disorders. Am J Psychiatry. 2005;162:2263-2268.
3. Yager J, Devlin M, Halmi K, et al. Guideline watch: practice guideline for the treatment of patients with eating disorders. Focus. 2014;12:416-431.
4. Vall E, Wade T. Predictors of treatment outcome in individuals with eating disorders: a systematic review and meta-analysis. Int J Eat Disord. 2016;49:432-433.
5. Hudson J, Hiripi E, Pope H, Kessler R. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psych. 2007;61:348-358.
6. Sansone R, Levitt J, Sansone L. The prevalence of personality disorders among those with eating disorders. Eat Disord. 2005;13:7-21.
7. Fischer S, Smith GT, Anderson KG. Clarifying the role of impulsivity in bulimia nervosa. Int J Eat Disord. 2003;33:406-411.
8. Bodell L, Joiner T, Keel P. Comorbidity-independent risk for suicidality increases with bulimia nervosa but not with anorexia nervosa. J Psychiatr Res. 2013; 47:617-621.
9. Svaldi JG, Tuschen-Caffier B, Ehring T. Emotion regulation deficits in eating disorders: a marker of eating pathology or general psychopathology? Psychiatr Res. 2012;15:103-111.
10. Trunko M, Kaye WH. Pharmacological treatment of bulimia nervosa: a review of available medications. Psychiatric Times. May 2008;25:52-58.
11. Bacaltchuk J, Hay P. Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst Rev. 2003;4:CD003391.
12. Berner L, Marsh R. Frontostriatal circuits and the development of bulimia nervosa. Front Behav Neurosci. 2014;17:395.
13. Bankoff S, Karpel M, Forbes H, Pantalone D. A systematic review of dialectical behavior therapy for the treatment of eating disorders. Eat Disord. 2012; 20:196-215.
14. Guerdjikova A, Blom T, Martens B, et al. Zonisamide in the treatment of bulimia nervosa: an open-label, pilot, prospective study. Int J Eat Disord. 2013;46:747-750.
15. Trunko M, Schwartz T, Marzola E, et al. Lamotrigine use in patients with binge eating and purging, significant affect dysregulation, and poor impulse control. Int J Eat Disord. 2014;47:329-334.
16. McElroy S, Guerdjikova A, Martens B, et al. Role of antiepileptic drugs in the management of eating disorders. CNS Drugs. 2009;23:139-153.
17. Trunko M, Schwartz T, Berner L, et al. A pilot open series of lamotrigine in eating disorders characterized by significant affect dysregulation and poor impulse control. Presented at: International Conference on Eating Disorders; June 2017; Prague, Czech Republic. Poster No. F004.
18. Keshen A, Helson T. Preliminary evidence for the off-label treatment of bulimia nervosa with psychostimulants: six case reports. J Clin Pharmacol. 2017; Epub ahead of print.
19. Trunko M, Schwartz T, Duvvuri V, Kaye WH. Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: case reports. Int J Eat Disord. 2011;44:269-275.
20. Takaki M, Okabe N. Aripiprazole may be effective as an add-on treatment in bulimic symptoms of eating disorders. J Clin Psychopharmacol. 2015;35: 93-95. ❒